Vol. 14 No. 1 (2022)

Artigos

• Health, income and obesity: an analysis for Brazilian states

  Márcio Luiz Ribeiro, Humberto Spolador

  8-20

  • PDF (Português (Brasil))

• Real world data: the economic impact of including oral antineoplastic agents for health care providers in the Brazilian Supplementary Health System

  Luciana Vasconcelos, Bernardo Pires, Bruna Rosa, Luciano Paladini, Marina Gaffo, Renato Picoli, Juares Bianco

  21-33

  • PDF (Português (Brasil))

• Hospitalization, mortality rates and costs associated with chronic obstructive pulmonary disease (COPD) in Distrito Federal, Brazil, before and after the change in 2018 state COPD protocol version – Real-world data

  Marcelo Rabahi, Rodrigo Scabello, Natália Santoni, Daniela Campos

  34-40

  • PDF (Português (Brasil))

• Blinatumomab in high-risk first relapse pediatric patients with acute lymphoblastic leukemia: a cost-effectiveness analysis

  Chrissy Beurden-Tan, Rodrigo Ribeiro, Adriana Seber, Maria Lucia Lee, Marina Marçola, Raphael Schuetz, Sandra Regina Loggetto, Angelo Maiolino

  41-50

  • PDF (Português (Brasil))

• Patient journey and survey of costs of monitoring initial and metastatic breast cancer in the Unified Health System (SUS)

  Renata Alcântara, Camila Milagres, Santusa Santana

  51-55

  • PDF (Português (Brasil))

• An update of a cost-effectiveness per response of adalimumab, etanercept, guselcumab, infliximab, ixekizumab, secukinumab and ustekinumab for treatment of moderate to severe plaque psoriasis from the perspective of the Brazilian Supplementary Health Syste

  Alexander Reininghaus, Rafael Gomes, Bernardo Pires, Juares Bianco, Renato Picoli, Henrique Santos, Gleison Duarte, Ricardo Romiti, André Carvalho

  56-62

  • PDF (Português (Brasil))

• Evaluation of bioequivalence between two rivaroxaban formulations – coated tablet 20 mg – administered under fasting and fed conditions in healthy volunteers

  Isabela César, Leonardo Teixeira, Florência Duarte, Flávia Bonetti, Michel Carvalho, Daniel Campos

  63-71

  • PDF (Português (Brasil))

• Budget impact analysis of PARP inhibitors in the first line maintenance treatment of patients with advanced, gBRCA mutated, ovarian cancer, from the perspective of the Brazilian supplementary health system

  Pamela Santana, Larissa Rodrigues, Vanessa Fabrício, Tatiana Lanças, Graziela Bernardino

  72-79

  • PDF (Português (Brasil))

• Cost analysis of sequencing new agents for the treatment of chronic lymphocytic leukemia from the perspective of the Brazilian supplementary health system

  Leandro Brust, Celso Arrais, Fabiano Pombo, Diego Kashiura, Pedro Vitor Lima, Ana Travassos, Rafael Silva, Straus Tanaka

  80-88

  • PDF (Português (Brasil))

• Willingness to pay and Contingent Valuation Method in the economic evaluation of pharmacy services

  César Rocha-Filho, Beatriz Castro, Matheus Marques, Nathalie Dewulf

  89-95

  • PDF (Português (Brasil))

• Statements about hemophilia A in Brazil: an expert Delphi panel

  Carlos Alberto Magliano, Ana Carolina Pereira, Roberta Fernandes, Yukie Sato-Kuwabara, Priscilla Loze, Nayara Carlos, Verónica Mata

  96-103

  • PDF (Português (Brasil))